Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

271
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
271
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.5K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

163
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
163
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Clinical Characteristics And Outcome Of Lung Cancer In Patients With Fibrosing Interstitial Lung Disease.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Clinical Characteristics And Outcome Of Lung Cancer In Patients With Fibrosing Interstitial Lung Disease.

Related Experiment Video

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K

Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease.

Soo Jin Han1, Hyeon Hwa Kim1, Dong-Gon Hyun1

  • 1Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.

BMC Pulmonary Medicine
|March 16, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

This study found no survival difference between idiopathic pulmonary fibrosis-lung cancer (IPF-LC) and non-IPF interstitial lung disease-lung cancer (ILD-LC) patients. Higher Krebs von den Lungen-6 levels and advanced lung cancer stage are poor prognostic factors in ILD-LC.

Keywords:
Idiopathic pulmonary fibrosisInterstitial lung diseaseKL-6Lung cancer

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

379
A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.5K

Related Experiment Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

379
A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.5K

Area of Science:

  • Pulmonology
  • Oncology
  • Medical Diagnostics

Background:

  • Interstitial lung disease (ILD) is a significant comorbidity in lung cancer (LC) patients, often associated with poor prognosis.
  • The clinical characteristics and outcomes of different ILD subtypes in LC patients require further investigation.
  • Understanding these differences is crucial for optimizing patient management and treatment strategies.

Purpose of the Study:

  • To compare the clinical characteristics and outcomes of patients with idiopathic pulmonary fibrosis-lung cancer (IPF-LC) versus non-IPF ILD-LC.
  • To identify independent prognostic factors for survival in patients with ILD-LC.

Main Methods:

  • Retrospective review of medical records for 163 patients diagnosed with ILD-LC.
  • Comparison of baseline characteristics and clinical outcomes between IPF-LC and non-IPF ILD-LC groups.
Prognosis
  • Prognostic factor analysis using the Cox proportional-hazard model.

    • Main Results:

    • No significant differences in clinical characteristics or mortality rates were observed between IPF-LC and non-IPF ILD-LC groups (median survival: 26 vs. 20 months).
    • Independent prognostic factors for ILD-LC survival included elevated Krebs von den Lungen-6 levels (≥1000 U/mL) and advanced clinical stage of LC.
    • Surgical treatment was a significant factor associated with improved survival (HR 0.235, p < 0.001).

    Conclusions:

    • Idiopathic pulmonary fibrosis-lung cancer (IPF-LC) and non-IPF ILD-LC patients exhibit similar survival rates.
    • Elevated Krebs von den Lungen-6 levels may serve as a valuable prognostic biomarker in ILD-LC patients.
    • Advanced LC stage and surgical intervention are key determinants of survival in this population.